Gene Therapy Market Size, Share, and Growth Forecast to 2034

According to Fortune Business Insights, the global gene therapy market size was valued at USD 4.29 billion in 2025 and is projected to grow from USD 5.2 billion in 2026 to USD 11.33 billion by 2034, exhibiting a CAGR of 10.20% during the forecast period. North America dominated the market with a share of 24.60% in 2025.

The global gene therapy market is witnessing strong growth due to rising investments in biotechnology, increasing prevalence of genetic disorders, and growing advancements in personalized medicine.

Gene therapy is a revolutionary treatment approach that modifies or replaces defective genes to treat or prevent diseases. The technology has gained substantial attention for its potential in treating rare inherited disorders, cancer, and neurological diseases. Rapid progress in CRISPR gene-editing technology, viral vector development, and stem cell research is further accelerating market expansion worldwide.

Information Source: https://www.fortunebusinessinsights.com/industry-reports/gene-therapy-market-100243 

Increasing Investments and Technological Advancements Fuel Market Growth

Increasing approvals of advanced gene therapies by regulatory agencies are driving industry growth. Pharmaceutical and biotechnology companies are heavily investing in research and clinical trials to develop innovative therapies for conditions that previously had limited treatment options. In addition, rising healthcare expenditure and growing awareness regarding precision medicine are positively influencing market demand.

The demand for gene therapy is particularly increasing in oncology applications. Researchers are developing therapies that target cancer cells by modifying genetic material, helping improve treatment outcomes. Moreover, therapies for rare diseases such as hemophilia, spinal muscular atrophy, and inherited retinal disorders are creating new growth opportunities for market participants.

Advancements in Viral Vectors Strengthen Industry Development

Technological advancements in viral vectors, including adeno-associated viruses and lentiviral vectors, have improved the safety and efficiency of gene delivery systems. These developments are helping manufacturers enhance therapeutic effectiveness while reducing adverse effects. Furthermore, collaborations between biotech firms, research institutes, and healthcare providers are strengthening innovation pipelines across the industry.

Despite strong growth potential, the market faces certain challenges. High treatment costs remain one of the major barriers limiting widespread adoption. Manufacturing complexities, regulatory hurdles, and concerns regarding long-term safety also affect market expansion. However, ongoing research activities and increased funding from public and private organizations are expected to support future commercialization efforts.

North America Dominates the Global Gene Therapy Market

North America continues to dominate the global gene therapy market due to the strong presence of leading biotechnology companies, advanced healthcare infrastructure, and significant R&D investments. The United States remains a major hub for clinical trials and product approvals. Europe is also witnessing considerable growth owing to favorable government support and increasing research collaborations.

Meanwhile, the Asia Pacific region is anticipated to experience rapid expansion during the forecast period. Countries such as China, Japan, and India are increasing investments in biotechnology and genomic research. Growing healthcare awareness, improving medical infrastructure, and rising patient populations are further supporting regional market growth.

COVID-19 Impact on the Gene Therapy Industry

The COVID-19 pandemic also accelerated advancements in genetic research and mRNA technologies, indirectly supporting innovations in gene therapy. Many pharmaceutical companies are now leveraging these technologies to expand their therapeutic pipelines and develop next-generation treatments.

Competitive Landscape

The competitive landscape of the market is characterized by strategic partnerships, mergers, acquisitions, and product launches. Major companies are focusing on expanding manufacturing capabilities and strengthening clinical trial programs to gain a competitive edge. Continuous innovation and regulatory approvals are expected to shape the future of the global gene therapy industry.

Key Players in the Gene Therapy Market

• Novartis AG

• CSL Limited

• F. Hoffmann-La Roche Ltd

• Pfizer Inc.

• Bluebird Bio, Inc.

• Sarepta Therapeutics

• Gilead Sciences, Inc.

• UniQure N.V.

FAQs

1. What is the size and share of the global gene therapy market?

The global gene therapy market was valued at USD 4.29 billion in 2025 and is projected to reach USD 11.33 billion by 2034, growing at a CAGR of 10.20% during the forecast period. North America held the largest market share of 24.60% in 2025.

2. What factors are driving the growth of the gene therapy market?

Major growth drivers include rising prevalence of genetic disorders, increasing investments in biotechnology research, advancements in CRISPR and viral vector technologies, and growing demand for personalized medicine.

3. Which region dominates the global gene therapy market?

North America dominates the market due to strong research infrastructure, favorable regulatory support, increasing clinical trials, and the presence of major biotechnology and pharmaceutical companies.